Switch theme
Sign up to access all valuation multiples
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
2013
430
LTM Revenue $242M
LTM EBITDA -$235M
-$521M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Arvinas has a last 12-month revenue of $242M and a last 12-month EBITDA of -$235M.
In the most recent fiscal year, Arvinas achieved revenue of $263M and an EBITDA of -$244M.
Arvinas expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Arvinas valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $78.5M | $263M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$395M | -$244M | XXX | XXX | XXX |
| EBITDA Margin | -503% | -92% | XXX | XXX | XXX |
| Net Profit | -$283M | -$367M | XXX | XXX | XXX |
| Net Margin | -360% | -139% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Arvinas's stock price is $7.
Arvinas has current market cap of $509M, and EV of -$521M.
See Arvinas trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$521M | $509M | XXX | XXX | XXX | XXX | $-3.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Arvinas has market cap of $509M and EV of -$521M.
Arvinas's trades at -2.2x LTM EV/Revenue multiple, and 2.2x LTM EBITDA.
Analysts estimate Arvinas's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Arvinas and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$521M | XXX | XXX | XXX |
| EV/Revenue | -2.0x | XXX | XXX | XXX |
| EV/EBITDA | 2.1x | XXX | XXX | XXX |
| P/E | -2.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 2.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpArvinas's NTM/LTM revenue growth is -21%
Arvinas's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $1.2M for the same period.
Over next 12 months, Arvinas's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Arvinas's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Arvinas and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 236% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -92% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -38% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -114% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.6M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 63% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 132% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 195% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arvinas acquired XXX companies to date.
Last acquisition by Arvinas was XXXXXXXX, XXXXX XXXXX XXXXXX . Arvinas acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Arvinas founded? | Arvinas was founded in 2013. |
| Where is Arvinas headquartered? | Arvinas is headquartered in United States of America. |
| How many employees does Arvinas have? | As of today, Arvinas has 430 employees. |
| Who is the CEO of Arvinas? | Arvinas's CEO is Dr. John G. Houston, PhD. |
| Is Arvinas publicy listed? | Yes, Arvinas is a public company listed on NAS. |
| What is the stock symbol of Arvinas? | Arvinas trades under ARVN ticker. |
| When did Arvinas go public? | Arvinas went public in 2018. |
| Who are competitors of Arvinas? | Similar companies to Arvinas include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Arvinas? | Arvinas's current market cap is $509M |
| What is the current revenue of Arvinas? | Arvinas's last 12-month revenue is $242M. |
| What is the current EBITDA of Arvinas? | Arvinas's last 12-month EBITDA is -$235M. |
| What is the current EV/Revenue multiple of Arvinas? | Current revenue multiple of Arvinas is -2.2x. |
| What is the current EV/EBITDA multiple of Arvinas? | Current EBITDA multiple of Arvinas is 2.2x. |
| What is the current revenue growth of Arvinas? | Arvinas revenue growth between 2023 and 2024 was 236%. |
| Is Arvinas profitable? | Yes, Arvinas is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
